GLP-1 Therapies Research,
what lands in your inbox each week:
- 📚7 fresh studies
- 📝plain-language summaries
- ✅direct links to original studies
- 🏅top journal indicators
- 📅weekly delivery
- 🧘♂️no ads
some of our latest newsletters:
(select one to read it below)
Among 6,700 obese patients, GLP-1s reduce heart surgery complications by 18%
GLP-1 drugs like Ozempic and Wegovy are proving to be much more than diabetes and weight loss medications. This week's research reveals surprising benefits for heart surgery patients and potential protection against neurodegeneration.
🫀 GLP-1 drugs slash heart surgery complications in obese patients
Among 6,700 obese patients undergoing atrial fibrillation ablation, those taking GLP-1 drugs had 18% fewer heart rhythm relapses compared to non-users (6.66% vs 7.72%)
GLP-1 users also had 27% lower risk of death and 20% fewer heart failure hospitalizations during 2-year follow-up
The benefits held even for patients without diabetes, suggesting the drugs' heart-protective effects go beyond blood sugar control
Why it matters: This real-world data from over 100 million patient records suggests GLP-1 drugs may become standard care before heart procedures, potentially preventing thousands of complications annually.
Key Findings
🧠 GLP-1 drugs may protect against Alzheimer's and Parkinson's
Clinical trials show GLP-1 drugs like liraglutide and lixisenatide can slow cognitive decline and motor symptoms in neurodegenerative diseases
The drugs appear to work by improving brain insulin signaling, reducing inflammation, and protecting neurons from damage
Japan is launching a major trial testing oral semaglutide in 99 Parkinson's patients to confirm disease-modifying effects
💊 New oral GLP-1 pills show promise for diabetes and weight loss
Two new oral GLP-1 drugs (danuglipron and orforglipron) reduced blood sugar by 0.9-1.0% and caused 2-6 kg weight loss in 1,454 patients
Orforglipron was more effective for weight loss but both caused gastrointestinal side effects in many users
Oral formulations could make these treatments more accessible than current weekly injections
⚡ GLP-1 drugs reduce insulin needs by 23% in type 1 diabetes
In 26-week study of type 1 diabetics using insulin pumps, semaglutide reduced total daily insulin by 22.6% compared to placebo
The effect was driven mainly by 30.5% reduction in mealtime insulin rather than background insulin
Early insulin reduction was due to direct drug effects, while later reductions came from weight loss
🏥 Semaglutide cuts hospital stays by 10% in heart disease patients
Among 17,604 overweight patients with heart disease, those on semaglutide had 10% fewer hospital admissions over 3.5 years
Total hospital days were reduced by 11%, saving an average of 19 days per 100 patients annually
Benefits extended beyond heart-related admissions to all-cause hospitalizations
🦴 GLP-1 drugs may increase fracture risk in older, severely obese patients
Analysis of 66,420 non-diabetic patients found 19% higher fracture risk with GLP-1 use (3.05% vs 2.61%)
Risk was concentrated in patients with BMI ≥40 and those over 68 years old, with fracture rates up to 9.3% in the oldest group
The mechanism may involve rapid weight loss affecting bone density or muscle mass
💰 Income inequality limits access to life-saving diabetes drugs
Among 30.3 million Americans with type 2 diabetes, those with above-median income were 61% more likely to receive semaglutide
Private insurance increased access by 52% compared to other coverage types
The disparity affects those most at risk for diabetes complications - low-income and minority populations
Implications
GLP-1 drugs are emerging as a transformative class of medications with benefits far beyond their original diabetes indication. However, expanding access and understanding long-term effects - both positive and negative - will be crucial as these drugs reshape modern medicine.
Science is the only real news.
The rest is just drama 📰
And nowadays, we see that drama everywhere.
Drama sells ads, ads sell products, and my attention sells to the highest bidder.
Drama media is junk food for the mind.
A quick rush, hard to avoid, but little nutritional value.
The brain wants broccoli 🧠🥦
And look, it's not that science never makes the news.
But think about when it does—does the news really understand the science it reports on?
Like it or not, AI exists now.
And it happens to be a huge science nerd… 🔭🤖
…with a superpower…
...unlike an average science nerd, AI can explain it simply.
I built OpenScience to make the constant stream of new studies accessible to anyone.
To free science from academic jargon and tiny-fonted PDFs.
OpenScience is a weekly newsletter of 7 compelling studies from the past week in the topic of your choice.
Made simple, digestible, and delightful by AI.
Interested in CRISPR?
The latest Long Covid research?
Psychedelic medicine?
Follow the actual science, as it comes out.
Every study is linked to the original PubMed so you can verify the AI's summary yourself.
Not supported by ads. Your attention is not the product.
My goal is for the science itself to be the product—and for that to be worth paying for.
Start your free trial in a topic of your choice today—and give your mind the broccoli it deserves 🥦
The real-time unfolding of science is too interesting not to follow.
The past week's glp-1 therapies research—translated into simple language by AI.
- $4/month for weekly issues
- 4 free issues to start
- 1st issue of the month is free to everyone